In life sciences the frontier runs straight into regulation and high-stakes evidence. Aging research, biodefense guardrails, FDA-grade evidence review — the recurring question is not whether AI can generate a result, but who decides which results, and which guardrails, become the default.
DeepMind's Co-Scientist mined tens of thousands of papers for 20-plus candidate genes to reverse cellular aging and cut a six-month analysis to days. But only two leads validated — what got faster was hypothesis generation and reading data, not proving anything works.
Read analysisOpenAI's AI biodefense action plan argues for equipping trusted defenders with frontier capability while building the safeguards and governance to deploy it. The real signal is that one capability raises both risk and defense — and where governance should move.
Read analysisOpenAI anchors scientific AI to workflows with LifeSciBench, then picks an FDA surrogate-endpoint case that mirrors Elevidys — exposing the real test for domain models: will they say the evidence isn't enough, exactly where the experts didn't agree?
Read analysis